Supernus initiated at MizuhoMizuho starts Supernus with Buy rating, $61 price target. Mizuho analyst Irina Koffler last night initiated coverage of Supernus Pharmaceuticals with a Buy rating and $61 price target. The company, with a "promising" pipeline that can drive growth through pending Trokendi XR competition in migraine, is well positioned in an attractive market, Koffler told investors in a research note.Read more at: https://thefly.com/landingPage...(Source theFly) * This stock has been on our trading list for a while now. Will continue to look for trades in this name. $SUPN, Supernus Pharmaceuticals, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. Follow us and check back occasionally for additional articles or posts.